Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis.
Saved in:
| Title: | Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis. |
|---|---|
| Authors: | Fissolo, Nicolás (AUTHOR), Benkert, Pascal (AUTHOR), Vilaseca‐Jolonch, Andreu (AUTHOR), Blanco, Yolanda (AUTHOR), Hegen, Harald (AUTHOR), Berek, Klaus (AUTHOR), Pérez‐Miralles, Francisco (AUTHOR), Rejdak, Konrad (AUTHOR), Villar, Luisa (AUTHOR), Monreal, Enric (AUTHOR), Alvarez‐Lafuente, Roberto (AUTHOR), Bachhuber, Franziska (AUTHOR), Tumani, Hayrettin (AUTHOR), Martínez‐Yelamos, Sergio (AUTHOR), Sánchez‐López, Antonio (AUTHOR), García‐Merino, Antonio (AUTHOR), Gutiérrez, Lucía (AUTHOR), Castillo‐Triviño, Tamara (AUTHOR), Lycke, Jan (AUTHOR), Rosenstein, Igal (AUTHOR) |
| Source: | European Journal of Neurology. Feb2026, Vol. 33 Issue 2, p1-4. 4p. |
| Subjects: | Microglia, Multiple sclerosis, Biomarkers, Disease progression |
| Abstract: | Background: Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglia surface receptor that aids in tissue repair and debris clearance. The soluble form, sTREM2, found in both blood and cerebrospinal fluid, is considered a biomarker for microglial activation. Based on the central role of microglia in MS pathogenesis, we aimed to investigate whether serum sTREM2 levels could predict disability progression in patients with primary progressive MS. Methods: Serum levels of sTREM2 were measured at baseline using a single‐molecule array assay in a multicenter cohort of 137 primary progressive multiple sclerosis (PPMS) patients. Univariable and multivariable linear models evaluated the association between sTREM2 levels and EDSS change at 2 years, 6 years, and last follow‐up. Results: While an association was observed at 2 years only in non‐inflammatory PPMS patients, no consistent relationship was found between sTREM2 levels and disability progression over longer follow‐up. Conclusions: These findings suggest that serum sTREM2 may have limited value as a biomarker of disability progression in PPMS. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglia surface receptor that aids in tissue repair and debris clearance. The soluble form, sTREM2, found in both blood and cerebrospinal fluid, is considered a biomarker for microglial activation. Based on the central role of microglia in MS pathogenesis, we aimed to investigate whether serum sTREM2 levels could predict disability progression in patients with primary progressive MS. Methods: Serum levels of sTREM2 were measured at baseline using a single‐molecule array assay in a multicenter cohort of 137 primary progressive multiple sclerosis (PPMS) patients. Univariable and multivariable linear models evaluated the association between sTREM2 levels and EDSS change at 2 years, 6 years, and last follow‐up. Results: While an association was observed at 2 years only in non‐inflammatory PPMS patients, no consistent relationship was found between sTREM2 levels and disability progression over longer follow‐up. Conclusions: These findings suggest that serum sTREM2 may have limited value as a biomarker of disability progression in PPMS. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.70480 |
